25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CSL Ltd
Buy, Hold or Sell?

Let's analyze Csl together

I guess you are interested in CSL Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of CSL Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about CSL Ltd

I send you an email if I find something interesting about CSL Ltd.

1. Quick Overview

1.1. Quick analysis of Csl (30 sec.)










1.2. What can you expect buying and holding a share of Csl? (30 sec.)

How much money do you get?

How much money do you get?
A$15.00
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
A$88.66
Expected worth in 1 year
A$115.70
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
A$49.25
Return On Investment
16.6%

For what price can you sell your share?

Current Price per Share
A$296.00
Expected price per share
A$287.43 - A$308.17
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Csl (5 min.)




Live pricePrice per Share (EOD)
A$296.00
Intrinsic Value Per Share
A$5.19 - A$114.16
Total Value Per Share
A$93.85 - A$202.82

2.2. Growth of Csl (5 min.)




Is Csl growing?

Current yearPrevious yearGrowGrow %
How rich?$29b$26.7b$2.2b7.8%

How much money is Csl making?

Current yearPrevious yearGrowGrow %
Making money$4b$3.3b$695.7m17.3%
Net Profit Margin18.0%17.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Csl (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#1 / 959

Most Revenue
#1 / 959

Most Profit
#1 / 959
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Csl?

Welcome investor! Csl's management wants to use your money to grow the business. In return you get a share of Csl.

First you should know what it really means to hold a share of Csl. And how you can make/lose money.

Speculation

The Price per Share of Csl is A$296.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Csl.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Csl, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$88.66. Based on the TTM, the Book Value Change Per Share is A$6.76 per quarter. Based on the YOY, the Book Value Change Per Share is A$17.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$5.55 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Csl.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps8.312.8%8.312.8%4.531.5%5.351.8%4.251.4%
Usd Book Value Change Per Share4.571.5%4.571.5%11.533.9%8.863.0%5.341.8%
Usd Dividend Per Share3.751.3%3.751.3%2.560.9%2.450.8%2.080.7%
Usd Total Gains Per Share8.312.8%8.312.8%14.084.8%11.313.8%7.412.5%
Usd Price Per Share199.36-199.36-187.31-190.95-145.74-
Price to Earnings Ratio23.99-23.99-41.34-37.65-34.51-
Price-to-Total Gains Ratio23.98-23.98-13.30-22.63-43.56-
Price to Book Ratio3.33-3.33-3.39-5.80-8.13-
Price-to-Total Gains Ratio23.98-23.98-13.30-22.63-43.56-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share199.8888
Number of shares5
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share3.752.45
Usd Book Value Change Per Share4.578.86
Usd Total Gains Per Share8.3111.31
Gains per Quarter (5 shares)41.5756.57
Gains per Year (5 shares)166.29226.28
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1759115649177216
215018332298355442
3225274488147532668
4300365654196709894
53754578202458861120
645054898629410641346
7525639115234312411572
8600730131839214181798
9675822148444115952024
10750913165049017732250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%30.01.01.093.8%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%24.08.00.075.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%32.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%29.03.00.090.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of CSL Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--6.7616.7610%17.067-60%13.125-48%7.902-14%
Book Value Per Share--88.65988.6590%81.898+8%59.771+48%37.078+139%
Current Ratio--2.1752.1750%2.009+8%2.378-9%2.622-17%
Debt To Asset Ratio--0.4900.4900%0.508-4%0.520-6%0.566-14%
Debt To Equity Ratio--1.0721.0720%1.166-8%1.146-6%1.384-22%
Dividend Per Share--5.5525.5520%3.789+47%3.630+53%3.076+80%
Eps--12.30512.3050%6.710+83%7.921+55%6.286+96%
Free Cash Flow Per Share--7.0147.0140%6.768+4%7.626-8%5.156+36%
Free Cash Flow To Equity Per Share--1.0341.0340%8.163-87%10.153-90%5.616-82%
Gross Profit Margin--0.6100.6100%0.564+8%0.654-7%0.625-2%
Intrinsic Value_10Y_max--114.160--------
Intrinsic Value_10Y_min--5.187--------
Intrinsic Value_1Y_max--8.467--------
Intrinsic Value_1Y_min--4.028--------
Intrinsic Value_3Y_max--27.706--------
Intrinsic Value_3Y_min--9.136--------
Intrinsic Value_5Y_max--49.675--------
Intrinsic Value_5Y_min--10.953--------
Market Cap143325274368.000+0%143235687419.470143235687419.4700%134309339879.040+7%136976834555.702+5%104527944883.291+37%
Net Profit Margin--0.1800.1800%0.170+6%0.205-12%0.203-12%
Operating Margin--0.2520.2520%0.223+13%0.268-6%0.271-7%
Operating Ratio--0.7480.7480%0.777-4%0.732+2%0.735+2%
Pb Ratio3.339+0%3.3303.3300%3.387-2%5.804-43%8.127-59%
Pe Ratio24.056+0%23.99123.9910%41.340-42%37.651-36%34.510-30%
Price Per Share296.000+0%295.210295.2100%277.380+6%282.768+4%215.814+37%
Price To Free Cash Flow Ratio42.201+0%42.08842.0880%40.983+3%37.771+11%53.480-21%
Price To Total Gains Ratio24.041+0%23.97723.9770%13.300+80%22.632+6%43.561-45%
Quick Ratio--0.8940.8940%0.757+18%1.150-22%1.199-25%
Return On Assets--0.0710.0710%0.061+16%0.095-26%0.124-43%
Return On Equity--0.1550.1550%0.141+10%0.212-27%0.305-49%
Total Gains Per Share--12.31212.3120%20.856-41%16.754-27%10.978+12%
Usd Book Value--29049478536.00329049478536.0030%26779417204.733+8%19555968397.481+49%12129800926.525+139%
Usd Book Value Change Per Share--4.5664.5660%11.526-60%8.863-48%5.336-14%
Usd Book Value Per Share--59.87159.8710%55.306+8%40.363+48%25.039+139%
Usd Dividend Per Share--3.7493.7490%2.559+47%2.451+53%2.077+80%
Usd Eps--8.3098.3090%4.531+83%5.349+55%4.245+96%
Usd Free Cash Flow--2298190246.9512298190246.9510%2213106520.892+4%2494465488.004-8%1686481449.033+36%
Usd Free Cash Flow Per Share--4.7374.7370%4.571+4%5.150-8%3.482+36%
Usd Free Cash Flow To Equity Per Share--0.6980.6980%5.512-87%6.856-90%3.792-82%
Usd Market Cap96787557780.710+0%96727059714.36896727059714.3680%90699097220.316+7%92500456375.466+5%70587721179.686+37%
Usd Price Per Share199.889+0%199.355199.3550%187.315+6%190.953+4%145.739+37%
Usd Profit--4031752079.5864031752079.5860%3336016945.544+21%3359385571.449+20%2563232135.725+57%
Usd Revenue--22417274054.19322417274054.1930%19584976492.906+14%16761554745.134+34%12858429495.757+74%
Usd Total Gains Per Share--8.3158.3150%14.084-41%11.314-27%7.413+12%
 EOD+4 -4MRQTTM+0 -0YOY+28 -85Y+17 -1910Y+22 -14

3.3 Fundamental Score

Let's check the fundamental score of CSL Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1524.056
Price to Book Ratio (EOD)Between0-13.339
Net Profit Margin (MRQ)Greater than00.180
Operating Margin (MRQ)Greater than00.252
Quick Ratio (MRQ)Greater than10.894
Current Ratio (MRQ)Greater than12.175
Debt to Asset Ratio (MRQ)Less than10.490
Debt to Equity Ratio (MRQ)Less than11.072
Return on Equity (MRQ)Greater than0.150.155
Return on Assets (MRQ)Greater than0.050.071
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of CSL Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.594
Ma 20Greater thanMa 50304.279
Ma 50Greater thanMa 100305.597
Ma 100Greater thanMa 200295.533
OpenGreater thanClose296.700
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Fundamental data was last updated by Penke on 2024-09-14 00:01:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is fair priced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Csl earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Csl to the Biotechnology industry mean.
  • A Net Profit Margin of 18.0% means that $0.18 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of CSL Ltd:

  • The MRQ is 18.0%. The company is making a huge profit. +2
  • The TTM is 18.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ18.0%TTM18.0%0.0%
TTM18.0%YOY17.0%+1.0%
TTM18.0%5Y20.5%-2.6%
5Y20.5%10Y20.3%+0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.0%-131.4%+149.4%
TTM18.0%-212.1%+230.1%
YOY17.0%-219.3%+236.3%
5Y20.5%-370.1%+390.6%
10Y20.3%-487.5%+507.8%
4.3.1.2. Return on Assets

Shows how efficient Csl is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Csl to the Biotechnology industry mean.
  • 7.1% Return on Assets means that Csl generated $0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of CSL Ltd:

  • The MRQ is 7.1%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 7.1%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ7.1%TTM7.1%0.0%
TTM7.1%YOY6.1%+1.0%
TTM7.1%5Y9.5%-2.5%
5Y9.5%10Y12.4%-2.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.1%-11.0%+18.1%
TTM7.1%-11.8%+18.9%
YOY6.1%-11.2%+17.3%
5Y9.5%-12.8%+22.3%
10Y12.4%-14.4%+26.8%
4.3.1.3. Return on Equity

Shows how efficient Csl is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Csl to the Biotechnology industry mean.
  • 15.5% Return on Equity means Csl generated $0.16 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of CSL Ltd:

  • The MRQ is 15.5%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 15.5%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ15.5%TTM15.5%0.0%
TTM15.5%YOY14.1%+1.4%
TTM15.5%5Y21.2%-5.7%
5Y21.2%10Y30.5%-9.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.5%-13.7%+29.2%
TTM15.5%-16.1%+31.6%
YOY14.1%-13.7%+27.8%
5Y21.2%-18.9%+40.1%
10Y30.5%-19.1%+49.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of CSL Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Csl is operating .

  • Measures how much profit Csl makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Csl to the Biotechnology industry mean.
  • An Operating Margin of 25.2% means the company generated $0.25  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of CSL Ltd:

  • The MRQ is 25.2%. The company is operating very efficient. +2
  • The TTM is 25.2%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ25.2%TTM25.2%0.0%
TTM25.2%YOY22.3%+2.9%
TTM25.2%5Y26.8%-1.6%
5Y26.8%10Y27.1%-0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ25.2%-286.0%+311.2%
TTM25.2%-285.5%+310.7%
YOY22.3%-241.7%+264.0%
5Y26.8%-386.0%+412.8%
10Y27.1%-495.6%+522.7%
4.3.2.2. Operating Ratio

Measures how efficient Csl is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.75 means that the operating costs are $0.75 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of CSL Ltd:

  • The MRQ is 0.748. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.748. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.748TTM0.7480.000
TTM0.748YOY0.777-0.029
TTM0.7485Y0.732+0.016
5Y0.73210Y0.735-0.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7482.768-2.020
TTM0.7483.284-2.536
YOY0.7773.432-2.655
5Y0.7324.971-4.239
10Y0.7356.542-5.807
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of CSL Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Csl is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.18 means the company has $2.18 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of CSL Ltd:

  • The MRQ is 2.175. The company is able to pay all its short-term debts. +1
  • The TTM is 2.175. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.175TTM2.1750.000
TTM2.175YOY2.009+0.166
TTM2.1755Y2.378-0.203
5Y2.37810Y2.622-0.244
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1753.740-1.565
TTM2.1753.919-1.744
YOY2.0094.741-2.732
5Y2.3786.002-3.624
10Y2.6226.336-3.714
4.4.3.2. Quick Ratio

Measures if Csl is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Csl to the Biotechnology industry mean.
  • A Quick Ratio of 0.89 means the company can pay off $0.89 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of CSL Ltd:

  • The MRQ is 0.894. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.894. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.894TTM0.8940.000
TTM0.894YOY0.757+0.136
TTM0.8945Y1.150-0.256
5Y1.15010Y1.199-0.048
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8943.142-2.248
TTM0.8943.448-2.554
YOY0.7574.734-3.977
5Y1.1505.870-4.720
10Y1.1996.479-5.280
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of CSL Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Csl assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Csl to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.49 means that Csl assets are financed with 49.0% credit (debt) and the remaining percentage (100% - 49.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of CSL Ltd:

  • The MRQ is 0.490. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.490. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.490TTM0.4900.000
TTM0.490YOY0.508-0.018
TTM0.4905Y0.520-0.030
5Y0.52010Y0.566-0.047
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4900.342+0.148
TTM0.4900.344+0.146
YOY0.5080.306+0.202
5Y0.5200.365+0.155
10Y0.5660.380+0.186
4.5.4.2. Debt to Equity Ratio

Measures if Csl is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Csl to the Biotechnology industry mean.
  • A Debt to Equity ratio of 107.2% means that company has $1.07 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of CSL Ltd:

  • The MRQ is 1.072. The company is able to pay all its debts with equity. +1
  • The TTM is 1.072. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.072TTM1.0720.000
TTM1.072YOY1.166-0.094
TTM1.0725Y1.146-0.074
5Y1.14610Y1.384-0.237
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0720.394+0.678
TTM1.0720.450+0.622
YOY1.1660.372+0.794
5Y1.1460.447+0.699
10Y1.3840.488+0.896
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Csl generates.

  • Above 15 is considered overpriced but always compare Csl to the Biotechnology industry mean.
  • A PE ratio of 23.99 means the investor is paying $23.99 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of CSL Ltd:

  • The EOD is 24.056. Based on the earnings, the company is fair priced.
  • The MRQ is 23.991. Based on the earnings, the company is fair priced.
  • The TTM is 23.991. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD24.056MRQ23.991+0.064
MRQ23.991TTM23.9910.000
TTM23.991YOY41.340-17.349
TTM23.9915Y37.651-13.659
5Y37.65110Y34.510+3.140
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD24.056-2.336+26.392
MRQ23.991-2.413+26.404
TTM23.991-2.983+26.974
YOY41.340-3.464+44.804
5Y37.651-6.036+43.687
10Y34.510-6.204+40.714
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of CSL Ltd:

  • The EOD is 42.201. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 42.088. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 42.088. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD42.201MRQ42.088+0.113
MRQ42.088TTM42.0880.000
TTM42.088YOY40.983+1.106
TTM42.0885Y37.771+4.318
5Y37.77110Y53.480-15.710
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD42.201-3.062+45.263
MRQ42.088-3.222+45.310
TTM42.088-3.541+45.629
YOY40.983-4.704+45.687
5Y37.771-8.070+45.841
10Y53.480-8.591+62.071
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Csl is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.33 means the investor is paying $3.33 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of CSL Ltd:

  • The EOD is 3.339. Based on the equity, the company is fair priced.
  • The MRQ is 3.330. Based on the equity, the company is fair priced.
  • The TTM is 3.330. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.339MRQ3.330+0.009
MRQ3.330TTM3.3300.000
TTM3.330YOY3.387-0.057
TTM3.3305Y5.804-2.474
5Y5.80410Y8.127-2.322
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.3391.832+1.507
MRQ3.3301.903+1.427
TTM3.3302.227+1.103
YOY3.3872.416+0.971
5Y5.8043.549+2.255
10Y8.1274.102+4.025
4.6.2. Total Gains per Share

2.4. Latest News of CSL Ltd

Does CSL Ltd still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from CSL Ltd to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2024-08-29
17:40
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of CSL Ltd.

4.8.2. Funds holding CSL Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2020-10-31Vanguard International Stock Index-Total Intl Stock Indx1.50999995-6883873--
2021-01-31Investment Managers Ser Tr-WCM Focused International Growth Fd0.87-3948049--
2020-12-31Europacific Growth Fund0.86-3893001--
2020-12-31Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund0.64-2901422--
2021-02-28iShares Core MSCI EAFE ETF0.45-2048678--
2021-02-28iShares MSCI Eafe ETF0.33000002-1505346--
2021-02-28Fidelity Series International Growth Fund0.29-1311613--
2021-02-28Fidelity International Index Fund0.2-888927--
2021-02-28JP Morgan ETF Tr-BetaBuilders Developed Asia ex-Japan ETF0.19-843766--
2020-10-31Vanguard Intl Equity Index Fds-FTSE All World ex U.S. Index Fund0.18000001-805734--
Total 5.5199999802503040900.0%
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-06-302021-06-302022-06-302023-06-302024-06-30
Long-term Assets Other  -2,550,374214,625-2,335,749-209,380-2,545,128-15,414,007-17,959,13530,037,29212,078,157



5.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets56,931,946
Total Liabilities27,882,009
Total Stockholder Equity25,998,353
 As reported
Total Liabilities 27,882,009
Total Stockholder Equity+ 25,998,353
Total Assets = 56,931,946

Assets

Total Assets56,931,946
Total Current Assets16,123,381
Long-term Assets40,808,565
Total Current Assets
Cash And Cash Equivalents 2,481,096
Net Receivables 4,143,146
Inventory 8,930,149
Other Current Assets 568,990
Total Current Assets  (as reported)16,123,381
Total Current Assets  (calculated)16,123,381
+/- 0
Long-term Assets
Property Plant Equipment 14,461,331
Goodwill 12,097,028
Long Term Investments 163,000
Intangible Assets 8,267,000
Long-term Assets Other 8,156,508
Long-term Assets  (as reported)40,808,565
Long-term Assets  (calculated)43,144,867
+/- 2,336,302

Liabilities & Shareholders' Equity

Total Current Liabilities7,411,844
Long-term Liabilities20,470,165
Total Stockholder Equity25,998,353
Total Current Liabilities
Short-term Debt 1,413,491
Short Long Term Debt 848,000
Accounts payable 1,298,196
Other Current Liabilities 4,436,625
Total Current Liabilities  (as reported)7,411,844
Total Current Liabilities  (calculated)7,996,312
+/- 584,468
Long-term Liabilities
Long term Debt 9,671,000
Capital Lease Obligations 1,664,000
Long-term Liabilities Other 450,000
Long-term Liabilities  (as reported)20,470,165
Long-term Liabilities  (calculated)11,785,000
+/- 8,685,165
Total Stockholder Equity
Common Stock557,000
Retained Earnings 23,975,444
Accumulated Other Comprehensive Income 2,022,909
Other Stockholders Equity -557,000
Total Stockholder Equity (as reported)25,998,353
Total Stockholder Equity (calculated)25,998,353
+/-0
Other
Capital Stock557,000
Cash and Short Term Investments 2,481,096
Common Stock Shares Outstanding 485,199
Current Deferred Revenue263,532
Liabilities and Stockholders Equity 56,931,946
Net Debt 15,761,024
Net Invested Capital 27,882,000
Net Working Capital 5,818,000
Property Plant and Equipment Gross 13,545,000
Short Long Term Debt Total 18,242,120



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-301998-06-301997-06-301996-06-301995-06-301994-06-301993-06-30
> Total Assets 
153,075
312,672
335,456
373,816
385,180
325,150
374,853
565,096
904,155
1,301,724
1,495,525
2,709,471
2,954,140
3,106,280
3,562,081
4,491,886
5,945,391
4,853,647
5,416,494
5,955,441
5,975,500
6,277,700
6,401,000
10,156,728
11,893,227
14,582,798
17,548,130
22,680,465
24,185,015
41,221,552
54,434,012
56,931,946
56,931,94654,434,01241,221,55224,185,01522,680,46517,548,13014,582,79811,893,22710,156,7286,401,0006,277,7005,975,5005,955,4415,416,4944,853,6475,945,3914,491,8863,562,0813,106,2802,954,1402,709,4711,495,5251,301,724904,155565,096374,853325,150385,180373,816335,456312,672153,075
   > Total Current Assets 
70,808
81,419
73,291
93,828
119,064
109,147
129,973
363,487
290,471
415,888
504,944
1,420,342
1,700,104
1,733,101
1,888,119
2,497,705
3,994,131
2,837,850
2,951,972
3,476,677
3,259,300
3,207,600
3,339,100
5,127,585
5,999,739
6,758,747
7,894,692
9,362,672
9,843,090
23,937,614
13,909,712
16,123,381
16,123,38113,909,71223,937,6149,843,0909,362,6727,894,6926,758,7475,999,7395,127,5853,339,1003,207,6003,259,3003,476,6772,951,9722,837,8503,994,1312,497,7051,888,1191,733,1011,700,1041,420,342504,944415,888290,471363,487129,973109,147119,06493,82873,29181,41970,808
       Cash And Cash Equivalents 
4,300
1,304
533
1,254
1,225
1,627
1,931
2,687
59,993
59,799
56,239
80,329
551,928
559,278
407,326
671,243
2,040,302
850,770
512,369
1,182,123
762,200
608,700
556,800
747,515
1,100,971
1,102,660
937,371
1,734,786
2,409,324
15,176,907
2,325,546
2,481,096
2,481,0962,325,54615,176,9072,409,3241,734,786937,3711,102,6601,100,971747,515556,800608,700762,2001,182,123512,369850,7702,040,302671,243407,326559,278551,92880,32956,23959,79959,9932,6871,9311,6271,2251,2545331,3044,300
       Short-term Investments 
0
0
0
0
32,210
24,325
28,498
246,060
60,870
60,446
0
0
0
5,841
504
1,448
689
407
19,230
1,842
500
300
2,600
806
5,200
1,600
400
3,300
4,800
4,200
9,000
0
09,0004,2004,8003,3004001,6005,2008062,6003005001,84219,2304076891,4485045,84100060,44660,870246,06028,49824,32532,2100000
       Net Receivables 
40,849
53,004
27,007
41,886
31,386
28,612
32,785
43,689
82,698
107,221
114,456
372,084
409,448
419,291
500,582
652,076
693,158
727,807
832,096
762,020
814,800
914,300
958,500
1,402,498
1,451,665
1,857,075
2,459,993
2,314,161
2,195,138
2,200,393
2,908,435
4,143,146
4,143,1462,908,4352,200,3932,195,1382,314,1612,459,9931,857,0751,451,6651,402,498958,500914,300814,800762,020832,096727,807693,158652,076500,582419,291409,448372,084114,456107,22182,69843,68932,78528,61231,38641,88627,00753,00440,849
       Inventory 
25,008
27,111
45,751
50,688
53,754
53,869
65,463
70,549
143,890
245,529
330,225
945,654
721,767
722,330
956,981
1,146,308
1,228,362
1,236,235
1,556,115
1,496,306
1,639,400
1,644,500
1,755,600
2,890,142
3,358,060
3,644,583
4,330,317
5,097,313
5,035,764
6,301,171
8,211,523
8,930,149
8,930,1498,211,5236,301,1715,035,7645,097,3134,330,3173,644,5833,358,0602,890,1421,755,6001,644,5001,639,4001,496,3061,556,1151,236,2351,228,3621,146,308956,981722,330721,767945,654330,225245,529143,89070,54965,46353,86953,75450,68845,75127,11125,008
       Other Current Assets 
975
0
0
0
489
715
1,295
502
3,888
3,339
4,024
22,275
16,961
6,889
22,726
26,630
12,174
22,630
32,161
5,300
7,224
743
26,563
86,624
89,042
154,429
167,011
216,412
202,864
259,143
464,208
568,990
568,990464,208259,143202,864216,412167,011154,42989,04286,62426,5637437,2245,30032,16122,63012,17426,63022,7266,88916,96122,2754,0243,3393,8885021,295715489000975
   > Long-term Assets 
82,267
231,253
262,165
279,988
266,116
216,003
244,881
201,609
613,685
885,836
990,580
1,289,128
1,254,037
1,373,179
1,673,963
1,994,181
1,951,260
2,015,797
2,464,522
2,478,765
2,716,200
3,070,100
3,061,900
5,029,143
5,893,488
7,824,051
9,653,438
13,317,792
14,341,925
17,283,938
40,524,300
40,808,565
40,808,56540,524,30017,283,93814,341,92513,317,7929,653,4387,824,0515,893,4885,029,1433,061,9003,070,1002,716,2002,478,7652,464,5222,015,7971,951,2601,994,1811,673,9631,373,1791,254,0371,289,128990,580885,836613,685201,609244,881216,003266,116279,988262,165231,25382,267
       Property Plant Equipment 
76,529
223,854
228,758
242,041
221,963
183,725
205,367
187,323
259,181
316,765
362,205
620,157
586,469
605,761
728,494
933,722
966,444
1,026,507
1,290,306
1,393,557
1,587,200
1,831,000
1,841,300
3,209,240
3,836,386
4,806,659
6,390,167
9,158,170
10,037,962
12,082,600
14,049,425
14,461,331
14,461,33114,049,42512,082,60010,037,9629,158,1706,390,1674,806,6593,836,3863,209,2401,841,3001,831,0001,587,2001,393,5571,290,3061,026,507966,444933,722728,494605,761586,469620,157362,205316,765259,181187,323205,367183,725221,963242,041228,758223,85476,529
       Goodwill 
2,163
2,228
1,290
320
0
0
0
0
343,090
523,113
552,363
549,098
495,851
545,726
556,120
643,430
611,985
613,640
761,676
688,438
687,500
731,100
705,300
905,587
897,334
1,491,507
1,570,075
1,724,328
1,582,551
1,726,605
12,137,009
12,097,028
12,097,02812,137,0091,726,6051,582,5511,724,3281,570,0751,491,507897,334905,587705,300731,100687,500688,438761,676613,640611,985643,430556,120545,726495,851549,098552,363523,113343,09000003201,2902,2282,163
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
500
3,905
5,070
8,389
14,117
20,691
21,500
402,900
173,000
163,000
163,000173,000402,90021,50020,69114,1178,3895,0703,9055001,000000000000000000000000
       Intangible Assets 
0
699
543
452
0
0
0
0
343,090
557,333
603,042
52,080
71,556
63,378
230,644
227,697
174,524
198,422
216,295
184,825
168,200
193,000
221,600
1,265,915
1,375,921
2,439,602
2,676,594
3,327,524
3,556,044
3,836,399
24,706,678
8,267,000
8,267,00024,706,6783,836,3993,556,0443,327,5242,676,5942,439,6021,375,9211,265,915221,600193,000168,200184,825216,295198,422174,524227,697230,64463,37871,55652,080603,042557,333343,09000004525436990
       Other Assets 
0
0
0
0
0
0
0
16,750
16,427
18,814
34,811
0
0
0
0
0
0
0
180,245
0
272,100
313,900
282,000
394,000
0
0
401,800
558,600
0
0
0
0
0000558,600401,80000394,000282,000313,900272,1000180,245000000034,81118,81416,42716,7500000000
> Total Liabilities 
48,315
81,350
100,203
104,840
111,589
82,877
97,873
91,288
457,154
584,952
631,243
1,259,406
1,372,330
1,629,748
1,637,697
1,807,138
1,536,559
1,271,279
1,521,532
2,446,937
2,968,700
3,115,700
3,654,100
6,661,966
7,721,791
9,009,813
10,015,675
13,141,322
12,971,562
20,022,541
27,654,173
27,882,009
27,882,00927,654,17320,022,54112,971,56213,141,32210,015,6759,009,8137,721,7916,661,9663,654,1003,115,7002,968,7002,446,9371,521,5321,271,2791,536,5591,807,1381,637,6971,629,7481,372,3301,259,406631,243584,952457,15491,28897,87382,877111,589104,840100,20381,35048,315
   > Total Current Liabilities 
26,408
32,176
39,642
44,070
53,305
47,496
65,008
65,092
143,491
229,034
163,980
488,082
406,195
765,453
676,561
799,795
989,161
668,745
1,011,177
959,228
906,600
845,300
936,100
1,845,823
2,109,510
2,591,460
3,118,204
3,110,385
4,133,999
10,336,945
6,922,557
7,411,844
7,411,8446,922,55710,336,9454,133,9993,110,3853,118,2042,591,4602,109,5101,845,823936,100845,300906,600959,2281,011,177668,745989,161799,795676,561765,453406,195488,082163,980229,034143,49165,09265,00847,49653,30544,07039,64232,17626,408
       Short-term Debt 
5,227
2,405
4,219
809
2,806
672
1,182
1,034
30,226
48,189
412
9,297
16,669
344,038
133,287
122,513
268,230
22,083
241,769
171,112
5,700
5,600
3,200
83,669
159,703
305,475
599,359
293,827
631,102
6,535,301
1,584,917
1,413,491
1,413,4911,584,9176,535,301631,102293,827599,359305,475159,70383,6693,2005,6005,700171,112241,76922,083268,230122,513133,287344,03816,6699,29741248,18930,2261,0341,1826722,8068094,2192,4055,227
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,890,300
2,280,900
80,528
155,226
301,312
595,323
180,679
396,000
4,420,500
964,000
848,000
848,000964,0004,420,500396,000180,679595,323301,312155,22680,5282,280,9001,890,300000000000000000000000
       Accounts payable 
5,891
13,623
14,649
15,867
25,489
21,867
32,640
34,428
72,165
116,583
130,525
162,491
111,970
100,985
150,136
153,682
219,385
178,626
261,538
222,998
261,100
213,900
257,800
407,601
520,175
564,932
602,209
665,650
696,637
860,612
1,231,879
1,298,196
1,298,1961,231,879860,612696,637665,650602,209564,932520,175407,601257,800213,900261,100222,998261,538178,626219,385153,682150,136100,985111,970162,491130,525116,58372,16534,42832,64021,86725,48915,86714,64913,6235,891
       Other Current Liabilities 
548
496
284
401
451
449
409
218
209
104,049
88,949
199,406
75,171
320,156
393,054
449
379
846
1,063
1,023
900
2,300
2,100
1,076,148
1,165,635
1,384,855
1,685,501
1,782,426
2,389,344
2,749,800
3,661,083
4,436,625
4,436,6253,661,0832,749,8002,389,3441,782,4261,685,5011,384,8551,165,6351,076,1482,1002,3009001,0231,063846379449393,054320,15675,171199,40688,949104,049209218409449451401284496548
   > Long-term Liabilities 
21,907
49,174
60,561
60,770
58,284
35,381
32,865
26,196
313,662
355,918
467,263
771,324
966,135
864,295
961,136
1,007,343
547,398
602,533
510,355
1,487,709
2,062,100
2,270,400
2,718,000
4,816,143
5,612,281
6,418,353
6,897,471
10,030,937
8,837,562
9,685,596
20,731,616
20,470,165
20,470,16520,731,6169,685,5968,837,56210,030,9376,897,4716,418,3535,612,2814,816,1432,718,0002,270,4002,062,1001,487,709510,355602,533547,3981,007,343961,136864,295966,135771,324467,263355,918313,66226,19632,86535,38158,28460,77060,56149,17421,907
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,277,700
3,081,000
3,852,700
4,160,600
4,242,200
4,831,700
5,333,100
5,163,800
11,172,000
0
011,172,0005,163,8005,333,1004,831,7004,242,2004,160,6003,852,7003,081,0002,277,7000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
31,498
29,926
54,231
77,050
187,868
336,267
507,777
197,052
134,074
184,788
157,930
165,287
239,800
273,900
258,000
440,300
540,100
488,100
619,300
632,700
1,005,200
1,338,900
1,496,500
2,628,000
0
02,628,0001,496,5001,338,9001,005,200632,700619,300488,100540,100440,300258,000273,900239,800165,287157,930184,788134,074197,052507,777336,267187,86877,05054,23129,92631,4980000000
> Total Stockholder Equity
104,760
231,327
235,253
268,976
273,591
242,274
276,980
473,807
447,002
716,772
864,282
1,450,065
1,581,810
1,476,532
1,924,384
2,684,748
4,408,832
3,582,369
3,894,962
3,508,504
3,006,800
3,162,000
2,746,900
3,447,757
4,124,633
5,521,960
7,483,149
9,480,901
11,163,903
21,199,011
23,715,166
25,998,353
25,998,35323,715,16621,199,01111,163,9039,480,9017,483,1495,521,9604,124,6333,447,7572,746,9003,162,0003,006,8003,508,5043,894,9623,582,3694,408,8322,684,7481,924,3841,476,5321,581,8101,450,065864,282716,772447,002473,807276,980242,274273,591268,976235,253231,327104,760
   Common Stock
52,913
94,991
92,326
102,375
97,968
81,487
155,874
353,049
304,347
520,131
630,966
1,050,414
932,560
737,672
868,483
989,597
2,227,626
968,196
271,355
-382,033
-1,978,300
-2,797,800
-3,560,400
-4,213,000
-4,534,300
-4,634,500
-4,603,000
-4,561,000
483,800
483,800
517,000
557,000
557,000517,000483,800483,800-4,561,000-4,603,000-4,634,500-4,534,300-4,213,000-3,560,400-2,797,800-1,978,300-382,033271,355968,1962,227,626989,597868,483737,672932,5601,050,414630,966520,131304,347353,049155,87481,48797,968102,37592,32694,99152,913
   Retained Earnings 
38,736
49,492
54,449
69,900
78,197
77,516
96,496
99,039
104,687
157,193
222,287
346,105
696,594
780,242
1,217,370
1,823,640
2,168,940
2,820,364
4,074,235
4,425,671
4,406,800
5,221,500
6,000,800
8,853,478
9,652,435
11,491,101
13,697,613
15,616,993
16,320,613
19,637,025
21,964,997
23,975,444
23,975,44421,964,99719,637,02516,320,61315,616,99313,697,61311,491,1019,652,4358,853,4786,000,8005,221,5004,406,8004,425,6714,074,2352,820,3642,168,9401,823,6401,217,370780,242696,594346,105222,287157,193104,68799,03996,49677,51678,19769,90054,44949,49238,736
   Accumulated Other Comprehensive Income 
13,111
86,844
88,478
96,700
97,426
83,271
24,610
21,720
37,968
39,449
11,028
53,546
-47,344
-41,382
-161,468
-128,490
12,266
-206,191
-450,628
-535,133
578,300
738,300
306,500
-5,405,721
-5,527,801
-5,969,141
-6,214,464
-6,136,093
-5,156,710
1,561,986
1,750,169
2,022,909
2,022,9091,750,1691,561,986-5,156,710-6,136,093-6,214,464-5,969,141-5,527,801-5,405,721306,500738,300578,300-535,133-450,628-206,19112,266-128,490-161,468-41,382-47,34453,54611,02839,44937,96821,72024,61083,27197,42696,70088,47886,84413,111
   Capital Surplus 00000000000000000000000000000000
   Treasury Stock000000-4,634,500-4,534,300-4,213,000-3,560,400-2,797,800-1,978,300-373,3000000000000000000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.